Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Neuroblastoma 6Osteosarcoma 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteoporosis 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Nerve Sheath Neoplasms 1Neoplasms 1Myoepithelioma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Gliosarcoma 1Glioma 1Glioblastoma 1Desmoplastic Small Round Cell Tumor 1Chordoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 10Temozolomide 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Cisplatin 6Filgrastim 5Etoposide 5Carboplatin 5Vincristine 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3fludarabine 2antineoplaston AS 2-1 2antineoplaston A10 2aldesleukin 2Thalidomide 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Biopsy 2Bevacizumab 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Zoledronic Acid × CNS × Clear all
NCT02508038 2025-10-16

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
22 enrolled
CNSLymphoidMyeloidOther hematologic neoplasmSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Leukemia, Myeloid, Acute, Neuroectodermal Tumors, Primitive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡